Two Sigma Investments
ACAD icon

Two Sigma Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Two Sigma Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-55,100
Closed -$1.59M – 2837
2016
Q4 		$1.59M Buy
+55,100
New +$1.46M 0.01% 1661

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Two Sigma Investments's ACAD Position: Q1 2026 in Review

Two Sigma Investments reduced its Acadia Pharmaceuticals (ACAD) stake by 31% in Q1 2026, selling an estimated $8.22M and leaving 775,121 shares worth $17.3M. The position accounts for 0.01% of the portfolio, ranked #1036.

Two Sigma Investments first reported a position in ACAD in Q4 2016 and has held it in 24 quarters since. The position peaked at $29.9M in Q4 2025. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Two Sigma Investments held 775,121 shares of Acadia Pharmaceuticals worth $17.3M as of Q1 2026.
  • Two Sigma Investments sold 343,996 Acadia Pharmaceuticals shares in Q1 2026, an estimated $8.22M.
  • Acadia Pharmaceuticals made up 0.01% of Two Sigma Investments's portfolio in Q1 2026, its #1036 holding.
  • Two Sigma Investments first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 24 quarters since.
  • Two Sigma Investments's Acadia Pharmaceuticals position peaked at $29.9M in Q4 2025.
  • 341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.